Evaluations โ€บ Cass Review ยท Last reviewed 2026-05-16

Cass Review (2024) โ€” full summary

Cass H. Independent Review of Gender Identity Services for Children and Young People: Final Report. NHS England, April 2024 โ€” 388 pages, with a series of systematic reviews carried out by the University of York. See also Hilary Cass in the people register and the entry in the timeline 2024-04.

Summary

The Cass Review is the most extensive independent evaluation of paediatric gender care to date, commissioned by NHS England and led by paediatrician Dr Hilary Cass. A series of systematic reviews was commissioned from the University of York, covering among others puberty suppression, masculinising/feminising hormones and the quality of international guidelines. The review describes the care of young people with gender dysphoria as an area of "remarkably weak evidence" and makes recommendations for a restructuring of services.

1. Commission and methodology

NHS England commissioned paediatrician Dr Hilary Cass OBE in autumn 2020 to conduct an independent review (source). The methodology included:

  • A series of independent systematic reviews by the University of York.
  • Appraisal of international guidelines and a survey of gender clinics in the UK and EU-15+ countries โ€” see comparative table.
  • Qualitative research with patients, parents, professionals and detransitioners.
  • Statistical analysis of GIDS cohort data.
  • Consultation with clinicians, policymakers and advocacy organisations.

2. Main conclusions

"This is an area of remarkably weak evidence, and yet results of studies are exaggerated or misrepresented by people on all sides of the debate to support their viewpoint. The reality is that we have no good evidence on the long-term outcomes of interventions to manage gender-related distress."

โ€” Cass Review, April 2024, foreword

  • The 2020 NICE evidence review summarised in the report found only small uncontrolled observational studies on puberty blockers, with results of low to very low certainty (source).
  • The improvement in mental health found in the original Dutch study was not found in the British early intervention study (source).
  • The current adolescent referral population is a different cohort from the one in earlier studies (source).
  • Every young person should receive a holistic assessment of their needs, including screening for neurodevelopmental conditions such as autism spectrum disorder and a mental health assessment (source).

3. Recommendations (selection)

  • GnRHa treatment only within a research setting with independent data collection.
  • Masculinising/feminising hormones can be considered from the age of 16, but with an extremely cautious clinical approach and a strong clinical rationale before the age of 18 (source).
  • A holistic assessment including screening for neurodevelopmental conditions, including autism spectrum disorder, and a mental health assessment.
  • Regional service delivery instead of one centralised clinic.
  • National follow-up system for outcomes.

4. Response from the academic community

The Royal College of Psychiatrists welcomed the final report and called it a comprehensive, evidence-based review (source). Criticism came from, among others, Noone et al. (2025), who concluded in BMC Medical Research Methodology that the systematic reviews made for the Cass Review have a high risk of bias (source), and from the UK Council of the British Medical Association, which adopted a motion in July 2024 criticising the Cass Review and the measures taken in its name (source).1

5. Policy consequences

According to the final report, NHS England has set out that puberty blockers will only be available under a research protocol (source). In Ireland, doctors of the National Gender Service have urged that Ireland follow the recommendations of the Cass Review (source).

See also

Footnotes

  1. Noone C, et al. BMC Med Res Methodol. 2025 (critical appraisal of the Cass Review).

Cass Review across the network

Other sites in this network also cover this topic: